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Plasma DYRK1A as a novel risk factor for Alzheimer’s
disease
N Janel1,10, M Sarazin2,10, F Corlier3,4,5, H Corne3,4, LC de Souza3,4,5, L Hamelin2, A Aka1, J Lagarde2, H Blehaut6, V Hindié7, J-C Rain7,
ML Arbones8, B Dubois3,4, MC Potier4, M Bottlaender9 and JM Delabar1
To determine whether apparent involvement of DYRK1A in Alzheimer’s disease (AD) pathology makes it a candidate plasma
biomarker for diagnosis, we developed a method to quantify plasma DYRK1A by immunoblot in transgenic mouse models having
different gene dosages of Dyrk1a, and, consequently, different relative protein expression. Then, we measured plasma DYRK1A
levels in 26 patients with biologically conﬁrmed AD and 25 controls (negative amyloid imaging available on 13). DYRK1A was
detected in transgenic mouse brain and plasma samples, and relative levels of DYRK1A correlated with the gene copy number. In
plasma from AD patients, DYRK1A levels were signiﬁcantly lower compared with controls (Po0.0001). Results were similar when
we compared AD patients with the subgroup of controls conﬁrmed by negative amyloid imaging. In a subgroup of patients with
early AD (CDR= 0.5), lower DYRK1A expression was conﬁrmed. In contrast, no difference was found in levels of DYRK1B, the closest
relative of DYRK1A, between AD patients and controls. Further, AD patients exhibited a positive correlation between plasma
DYRK1A levels and cerebrospinal ﬂuid tau and phosphorylated-tau proteins, but no correlation with amyloid-β42 levels and
Pittsburgh compound B cortical binding. DYRK1A levels detected in lymphoblastoid cell lines from AD patients were also lower
when compared with cells from age-matched controls. These ﬁndings suggest that reduced DYRK1A expression might be a novel
plasma risk factor for AD.
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INTRODUCTION
An estimated 24 million people worldwide have dementia, and
this number, predicted to double every 20 years, will rise to more
than 65 million in 2030.1 The most common form of dementia,
Alzheimer’s disease (AD) represents a major public health concern
and has been identiﬁed as a research priority. Identifying blood
biomarkers of AD is critical to improving early diagnosis and
selecting patients who would beneﬁt from new disease-modifying
therapies. Such tools should detect speciﬁc features of the disease,
have high sensitivity and speciﬁcity for AD, and be reliable,
reproducible, noninvasive, easy to perform and low cost.
Current pathophysiological biomarkers are limited to amyloid
imaging with positron emission tomography (PET) and cerebrosp-
inal ﬂuid (CSF) biomarkers, including total tau (T-tau), phosphory-
lated tau (p-tau) and beta-amyloid peptide 1–42 (Aβ42)
measures.2 These tests can distinguish controls from individuals
with AD with high sensitivity and speciﬁcity, even in the early
stages of the disease.3 However, CSF collection is invasive and
requires brief hospitalization, whereas PET imaging is costly and
not always readily accessible. Therefore, blood-based biomarkers
of AD may be of great interest.
Most studies have tried to identify plasma markers of amyloid
pathology in accordance with the amyloid hypothesis, which
places amyloid at the heart of AD pathogenesis.4 However, clinical
signs of AD are more closely associated with cortical progression
of the neuroﬁbrillary tangles than amyloid plaques. Neuroﬁbrillary
tangles comprise insoluble aggregates of hyperphosphorylated
tau protein. Phosphorylation of tau regulates its capacity to form
oligomers and aggregates. Once ﬁlamentous tau has formed, it
can be transmitted to other brain regions. Many phosphokinases,
including glycogen synthase kinase 3β (GSK3β), have been
implicated in the phosphorylation of tau protein. DYRK1A (dual
speciﬁcity tyrosine-phosphorylation-regulated kinase 1A) is known
to phosphorylate numerous proteins involved in a wide variety of
signalling pathways.5 In AD, DYRK1A primes tau molecules for
further phosphorylation by GSK3β;6,7 it might also be important in
linking Aβ and tau pathology because it is upregulated by Aβ.8
Polymorphisms in phosphokinases, such as DYRK1A, might be
associated with an increased risk of AD.9 DYRK1A is encoded from
within the Down syndrome chromosomal region10 on human
chromosome 21, and current research suggests that overexpres-
sion of DYRK1A may be a signiﬁcant factor leading to cognitive
deﬁcits in people with AD and Down syndrome.
This study sought to determine whether apparent involvement
of DYRK1A in AD pathology makes it a candidate biomarker for
the diagnosis of AD. First, we developed an experimental animal
approach to detect and quantify DYRK1A levels in mouse plasma.
Then we used this method to analyse human plasma DYRK1A
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levels in patients with AD biologically conﬁrmed (positive CSF
biomarkers and PiB-PET) and controls deﬁned by normal cognitive
performances and negative PiB-PET imaging.
MATERIALS AND METHODS
Identiﬁcation and quantiﬁcation of DYRK1A
Experimental mice. We conducted a ﬁrst experimental animal study using
murine BAC clones containing the entire Dyrk1a gene, as previously
described.11 Mice were housed in standard cages with access to food and
water ad libitum, under a controlled environment (temperature = 20 ± 1 °C;
humidity = 60%), and with a light/dark cycle of 12 h. All experiments were
conducted in accordance with the ethical standards of French and
European regulations (European Communities Council Directive, 86/609/
EEC). Ofﬁcial authorization from the French Ministry of Agriculture was
granted to carry out research and experiments on animals (authorization
number 75–369). The study was approved by the local ethical committee
(Univ Paris Diderot). Mice carrying the murine BAC containing one copy of
Dyrk1a were maintained on a C57BL/6J background; Dyrk1a(+/− ) mice
were maintained on a CD1 background and genotyped as described.11
Mice were anesthetized and blood was collected through retro-orbital
sinus sampling into tubes containing a 1/10 volume of 3.8% sodium citrate.
Plasma was isolated by centrifugation at 2500 g. Mouse brains were
collected and frontal cortices were dissected.
Protein puriﬁcation and quantiﬁcation. Western blots were processed as
described previously.11,12 Proteins separated by SDS–PAGE were trans-
ferred to a nitrocellulose membrane (ProtanR) using a slot blot apparatus
(Proteigene, St Marcel, France). Membranes were saturated by incubation
in 5% w/v nonfat milk powder in Tris–saline buffer (1.5 mM Tris base, pH 8;
5 mM NaCl; 0.1% Tween-20) and incubated overnight at 4 °C with
antibodies against DYRK1A (1/250; Abnova Corporation, Taipei, Taiwan;
H00001859-M01). Binding of the primary antibody was detected by
incubation with HRP-conjugated secondary antibody using the Western
Blotting Luminol Reagent (Santa Cruz Biotechnology, Tebu, France).
Ponceau-S coloration was used as an internal control. Digitized images
of the immunoblots obtained using an LAS-3000 imaging system (Fuji
Photo Film, Paris, France) were used for densitometric measurements with
an image analyser (UnScan It software, Silk Scientiﬁc, Orem, UT, USA). All
assays were performed in duplicate. In addition, human brain frontal cortex
was obtained (control from La Salpetrière Hospital Brain Bank) and proteins
were analysed with the same method.
Brain and plasma DYRK1A quantiﬁcation. Using yeast two-hybrid, we
screened a highly complex random-primed human adult brain cDNA
library to identify genes encoding DYRK1A-interacting proteins. The assay
Figure 1. DYRK1A expression in plasma as detected by immunoblot. Western blotting of (a) DYRK1A expression in mouse and human frontal
cortex; and (b) DYRK1A expression in human plasma. Slot blot analysis of relative DYRK1A protein levels in: (c) cortex of Dyrk1a(+/− ) mice (120-
day-old males) in light grey versus wild-type mice (WT); (d) cortex of mBACtgDyrk1a mice (120-day-old males) in dark grey versus WT; (e) plasma
of Dyrk1a(+/− ) mice; and (f) plasma of mBACtgDyrk1a mice. Box plots indicate median with min to max, *Po0.05; a.u., arbitrary unit.
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identiﬁed 79 DYRK1A interactants (data not shown). Of these, 54 were from
the extracellular matrix, like clusterin, an abundant protein in plasma.13
DYRK1B, the closest member within the DYRK family of proteins (81%
identity for the central 427 amino acids) but not functionally overlapping
with DYRK1A, was used as a negative control in a second yeast two-hybrid
experiment. Most interactants of DYRK1B were intracellular proteins that
differed from those interacting with DYRK1A; there were some extracellular
common preys, including clusterin and MAGEH1. From DYRK1A sequence,
we hypothesized that the histidine-rich domain of DYRK1A could interact
with cysteine-rich regions (like those present in the EGF motif) and
generate false-positives in the yeast two-hybrid experiment. We thus ran
one by one yeast two-hybrid experiments using a mutated form of
DYRK1A lacking the histidine-rich domain and some extracellular preys:
ABHD12, MAGEH1 and clusterin: we conﬁrmed the interaction of DYRK1A
with these preys.
To determine whether interactions with extracellular matrix proteins and
other plasma proteins signalled the likely presence of DYRK1A in plasma,
we performed western blotting using human albumin-depleted plasmas.
Long DYRK1A isoforms migrating at the same apparent molecular weight
(80–85 kDa) as the isoforms from human and mouse frontal cortex were
detected using a DYRK1A mouse monoclonal antibody (Figures 1a and b)
and two different rabbit DYRK1A polyclonal antibodies (data not shown),
all raised against the carboxy terminus of DYRK1A.
To assess the relative amount of DYRK1A in plasma we used a slot blot
method previously developed for the quantiﬁcation of a large number of
brain homogenates from transgenic mice.11 Along with quantifying plasma
DYRK1A in wild-type mice, we used two different models carrying altered
gene copy numbers for Dyrk1a: a mBACtgDyrk1a model with three copies
of the murine Dyrk1a gene and a Dyrk1a(+/− ) model with only one copy.14
Clinical research
Population. Fifty-one participants were recruited in the Memory and
Alzheimer Institute of the Pitié-Salpêtrière Hospital, including 30 subjects
from the Biomage study (ANR-07-LVIE-002–01). Twenty-six biologically
conﬁrmed AD patients (n= 11 with clinical dementia rating (CDR) = 0.5;
n= 15 with CDR⩾ 1) were included using the following criteria: (1)
predominant and progressive episodic memory impairment, characterized
by low free recall not normalized with cueing, associated or not with other
cognitive deﬁcits;15 and (2) biological evidence of AD from CSF AD
biomarker proﬁle and/or signiﬁcant amyloid retention on positron
emission tomography (PET) with 11C-labelled Pittsburgh compound B
[11C-PiB]. A ‘CSF AD biomarker proﬁle’ was deﬁned as score below 0.8 for
the ratio of Aβ42:tau, calculated with the formula Aβ42/[240+(1.18 × T-
tau)].16,17 Signiﬁcant ﬁxation of PiB on PET was deﬁned by a global cortical
index higher than 1.4.16,17 Twenty-one patients had lumbar puncture, 17
patients had PiB-PET (12 patients had both lumbar puncture and PiB-PET
exam). We excluded subjects who presented with the following: (1) clinical
or neuroimaging evidence of focal lesions, (2) severe cortical or subcortical
vascular lesions or (3) severe depression.
Twenty-ﬁve healthy controls were selected according to the following
criteria: (1) Mini-Mental State Exam ⩾ 27, normal neuropsychological
testing and normal neurological exam; (2) no neurological or psychiatric
history; and (3) global index for 11C-PiB retention lower than 1.4 when PiB-
PET was available (n= 13).
Both groups were matched for age (Table 1).
The study was approved by the Ethics Committee of Pitié-Salpêtrière
Hospital. All the subjects provided written informed consent before
participating.
Measurement of CSF biomarkers
CSF samples were collected by lumbar puncture and analysed for total tau,
tau phosphorylated at threonine 181 (p-tau), and Aβ42 with a double-
sandwich enzyme-linked immunosorbent assay method (Innogenetics,
Gent, Belgium) at the Metabolic Biochemistry Department at the Pitié-
Salpêtrière Hospital, as described elsewhere.18 Controls had no lumbar
puncture for ethical reasons.
11C-PiB-PET imaging procedures
PET imaging with 11C-labelled PiB was performed in 13 controls and in 17
AD patients included in the Biomage study, using previously described
methods.17 In brief, a global cortical index was deﬁned by the mean
standard uptake value ratio (with the cerebellum as the reference region)
of the following cortical regions: (i) frontal cortex, by grouping the
orbitofrontal, polar prefrontal and dorsolateral cortex; (ii) anterior
cingulate; (iii) medial cingulate; (iv) posterior cingulate; (v) precuneus; (vi)
occipital cortex, by grouping the calcarine cortex, occipital cortex and
cuneus; (vii) temporal cortex, by grouping the anterior and lateral temporal
cortex; (viii) hippocampus and (ix) parietal cortex, by grouping the inferior
and superior parietal cortex and the parieto-temporal junction.
Blood collection and processing
Blood samples were collected from participants into citrate containers, and
the containers were immediately placed on ice until processed. Plasma was
obtained by centrifugation of containers for 15min at 2000 g at 4 °C, then
rapidly frozen and stored at − 80 °C until analysis. Plasma and serum
aliquots were thawed on the same day of the experiment. Plasma was
diluted at 1:20 in 1 × phosphate-buffered saline.
To identify and quantify plasma DYRK1A, the same technique developed
in mouse plasma was applied to plasma from individuals with AD and age-
matched control individuals.
In addition, for subjects included in the Biomage study (n= 30), APOE
genotypes were analysed.
Cell cultures
Epstein–Barr virus-transformed lymphoblastoid cell lines (LCLs) were
derived from B lymphocytes of late-onset AD patients and from
nondemented age-matched control individuals. LCLs were cultured in
Opti-MEM with GlutaMax (Invitrogen, Cergy, France) supplemented with
5% fetal bovine serum from a unique batch and 1% penicillin and
streptomycin mix (10 000 Uml− 1). Cell lines were grown at 37 °C in
humidiﬁed incubators under 5% CO2 and collected at a cell density below
3× 105.
Statistical analysis
Results are expressed as mean± s.e.m. Normality was assessed using the
Kolmogorov–Smirnov test. Statistical analysis was performed with
unpaired t-test and two-tailed P-values for comparison of means between
two groups using Prism6 (Graphpad) software, which calculates the exact
P-value and accounts for ties among values. Correlations were assessed
with nonparametric Spearman's rank correlation test. Data were consid-
ered signiﬁcant when P⩽ 0.05. A P-value of 0.06–0.10 was considered to
indicate a strong statistical tendency due to the small sample size.
RESULTS
Dyrk1a in brain and plasma of transgenic mouse models having
different gene dosage of Dyrk1a
After showing that long DYRK1A isoforms from human and mouse
frontal cortex migrated at the same apparent molecular weight
using the highly speciﬁc monoclonal antibody, we used immuno-
blot to analyse plasma DYRK1A in transgenic mouse models (see
Materials and methods, Figures 1c and d). DYRK1A was detected
in mouse plasma samples (Figures 1e and f). In addition, relative
levels of DYRK1A correlated with the gene copy number for
Table 1. Demographic and clinical data of studied groups
Controls AD
Number of subjects 25 26
Female (F)-male (M) 12 F/13M 13 F/13M
Age (years) 67.9± 1.7 64.1± 1.6
Disease duration (years) 3.5± 0.3
Mini-Mental State
Examination
29.08± 0.19 18.8± 1.1***
Clinical dementia rating
scale
0; n= 25 0.5: n= 11; 1: n= 14; 2:
n= 1
Abeta (4500) 280.0± 22.8
Tau (o450) 674.2± 71.5
P-tau (o60) 99.03± 8.7
Abbreviation: AD, dementia in Alzheimer’s disease. ***Po0.001.
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Dyrk1a in the transgenic mouse models carrying different gene
copy numbers.
Comparison of DYRK1A and DYRK1B in plasma of AD patients and
controls
Using the same method as in mouse, we detected DYRK1A in
human plasma. Mean relative DYRK1A expression was signiﬁcantly
lower in AD patients as compared with controls (Po0.0001;
Figure 2a). As a control, we assessed expression of DYRK1B (or
MIRK), a member of the same kinase family as DYRK1A, which
presents a different pattern of expression and is expressed at low
levels in the brain.19 This protein has been detected previously in
plasma (plasma protein database). Plasma samples from a
subgroup of CTRL and AD patients were analysed with the same
slot blot method. Relative DYRK1B expression was similar between
groups (Figure 2b). Further, in the subgroup of patients with early
AD (CDR= 0.5), the same decrease in DYRK1A expression was
found (Figure 2c). When we compared DYRK1A levels between AD
patients and controls for whom PiB-PET imaging was available
(n= 17 AD patients with positive amyloid imaging and n= 13
controls with negative amyloid imaging), we observed similar
results (Figure 3a). No difference was found in plasma DYRK1A
levels in AD patients at an early stage (CDR= 0.5) and AD patients
at a dementia stage (CDR⩾ 1). DYRK1A protein levels were not
correlated with the Mini-Mental State Exam scores.
The results were the same when stratifying by gender, therefore
results for both sexes are presented jointly.
Correlations between DYRK1A plasma levels and both CSF
biomarkers and PiB-PET in AD patients
When we analysed the correlations between plasma DYRK1A and
CSF biomarkers in the AD group, we found positive correlations
with both p-tau protein (P= 0.02, r= 0.53), and total tau (P= 0.05,
r= 0.45), but no correlation with Aβ42 levels (P= 0.06, r= 0.51;
Figures 4a–c). No correlation was found between PiB cortical index
and DYRK1A levels.
Stratiﬁcation by APOE genotype
The mean DYRK1A level in individuals (CTRL and AD) with the
APOE4 allele was signiﬁcantly lower than that of individuals with
either the APOE2 or APOE3 genotype (P= 0.03; Figure 3b). The level
of DYRK1A in AD individuals with an ApoE4 genotype is very
signiﬁcantly decreased in comparison with controls (Po0.0001).
Interestingly, the level of DYRK1A in individuals with AD who did
not have the APOE4 allele was also signiﬁcantly lower than that of
controls (P= 0.01).
DYRK1A expression in LCLs from AD patients
Lymphoblastoid cell lines established from lymphocytes of AD
patients and controls were grown in standard medium. They were
used to isolate proteins for quantiﬁcation of DYRK1A by slot blot.
Relative DYRK1A expression in LCLs was signiﬁcantly lower in AD
than in controls (Po0.05; Figure 5).
DISCUSSION
This study aimed to determine whether DYRK1A, a brain kinase
involved in AD pathology, may be a plasma biomarker for the
diagnosis of AD. First, we developed a method to quantify plasma
DYRK1A by immunoblot in transgenic mouse models having
different gene dosage of Dyrk1a, and, consequently, different
relative protein expression. DYRK1A was detected in brain mouse
and plasma samples. Levels of DYRK1A correlated with the gene
copy number, demonstrating that the highly speciﬁc monoclonal
antibody was able to detect changes in expression of DYRK1A in
plasma due to altered gene copy number in transgenic mice.
Using immunoblotting, we assessed the potential of plasma
DYRK1A level to differentiate AD patients from controls. We
applied strict inclusion criteria for AD based on both neuropsy-
chological deﬁcits and biological evidence of AD underlying
pathophysiology, including typical AD CSF biomarker proﬁles and
positive amyloid 11C-PiB-PET imaging. In addition, all controls
who underwent PiB-PET (13/25) had no cortical amyloid retention,
thus excluding presymptomatic AD.
Figure 2. DYRK1 protein levels in plasma from control (CTRL) individuals and Alzheimer’s disease (AD) patients. Slot-blotting was used to
detect relative expression of (a) DYRK1A in CTRL and AD; (b) DYRK1B in CTRL and AD; (c) DYRK1A in CTRL and early-stage AD. White dots:
controls; black dots: AD patients. Graph bars indicate mean± s.e.m; ****Po0.0001; ***Po0.001; a.u., arbitrary unit.
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We found that DYRK1A was expressed at signiﬁcantly lower
levels in plasma from AD patients compared with controls.
DYRK1A levels were 23% lower in AD patients, with few samples
overlapping the mean for the control group. Three ranges of
relative DYRK1A expression were detected among all samples:
high (150 to 100 arbitrary units), corresponding to controls only;
intermediate (100 to 75), with controls and AD patients; and low
(o75), with no controls. In contrast, levels of DYRK1B were not
signiﬁcantly different in AD and controls.
The DYRK family consists of ﬁve mammalian subtypes including
1A, 1B, 2, 3 and 4, of which only the gene encoding DYRK1A is
located on human chromosome 21, as is the gene encoding
amyloid precursor protein. DYRK1A has been shown to be
expressed ubiquitously, but is abundant in the cerebellum,
olfactory bulb and hippocampus.5 Increased activity of DYRK1A
has been reported in various brain compartments in individuals
with Down syndrome and neurodegenerative diseases including
AD. In particular, the percentage of DYRK1A-positive nuclei in the
frontal cortex of AD brains is about 10% compared with 0.5% in
normal brains.20 Evidence is accumulating to suggest that the
activity of DYRK1A is involved in regulating a multitude of cellular
pathways, especially by phosphorylation of a variety of proteins.
DYRK1A-mediated tau phosphorylation has also been shown to
promote further tau phosphorylation at multiple sites by GSK3β,
which increases the accumulation of DYRK1A-positive neuroﬁbril-
lary tangles.8 In addition, overactivity of DYRK1A has also been
implicated in increased proteolytic cleavage of amyloid precursor
protein, contributing to increased production of neurotoxic Aβ
peptides.21 These combined observations implicate DYRK1A in the
generation of both amyloid and tau pathologies associated with
Down syndrome and AD. However, the speciﬁcity of DYRK1A
in vivo remains poorly deﬁned.
We demonstrate here, for the ﬁrst time, that DYRK1A can be
detected in human plasma and that the plasma levels of DYRK1A
expression may distinguish between AD patients and controls.
Interestingly, we observed the same amplitude of decrease in the
Figure 3. DYRK1A protein levels stratiﬁed (a) according to PIB values with PIBo1.4 and PIB41.4; and (b) according to APOE genotype with ‘no
ApoE4’ for APOE2 or APOE3 genotypes and ‘ApoE4’ for one or two APOE4 alleles. White dots: controls; black dots: Alzheimer's disease patients.
Graph bars indicate mean± s.e.m; ***Po0.001; **Po0.01; a.u., arbitrary unit; PIB, Pittsburgh compound B.
Figure 4. Correlation analysis between level of CSF markers and DYRK1A level. (a) Aβ42 level and DYRK1A level; (b) tau level and DYRK1A level;
(c) p-tau level and DYRK1A level. Correlation was assessed with nonparametric Spearman's rank correlation test. Graphs show regression lines
with a 95% conﬁdence interval; a.u., arbitrary unit; CSF, cerebrospinal ﬂuid; p-tau, phosphorylated tau.
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subgroup of very mild AD patients (CDR= 0.5), suggesting that
DYRK1A could be useful to detect AD even at an early stage.
Furthermore, the results were similar when we restricted the
comparison between AD patients and ‘true’ controls deﬁned by
negative amyloid imaging.
In the DYRK family, DYRK1B, which is closely related to DYRK1A,
is highly expressed in the testis and skeletal muscle and mediates
muscle differentiation,22 cell survival and cell migration. Contrary
to DYRK1A, DYRK1B is not known to be involved in AD pathology.
DYRK1B was previously detected in human plasma.23 We have
therefore compared DYRK1B in AD patients and controls. In
accordance with our hypothesis, we found no difference between
both groups.
We analysed the correlations between plasma DYRK1A and
other pathophysiological markers of AD. We observed a positive
correlation with CSF tau and p-tau measures. These results agree
with previous reports from cellular models and mouse models, in
which increased expression of DYRK1A induces increased expres-
sion of tau and p-tau proteins.8,24 On the other hand, DYRK1A
protein levels were not correlated with CSF amyloid peptide and
cortical amyloid load assessed by PiB-PET. These results suggest
that lower expression of DYRK1A in plasma of AD patients may
reﬂect the impact of tau pathology more than amyloid
pathology in AD.
Another pathophysiological hypothesis is based on the role of
DYRK1A in inﬂammation. We showed recently that decreased
DYRK1A induces diabetes with a decreased pancreatic beta cell
mass.25 We also previously demonstrated in another peripheral
organ, liver, that decreased DYRK1A induces NF-kappaB activation
and increased inﬂammation.26 In contrast, increased DYRK1A is
associated with increased NRF2 and decreased NF-kappaB
activation.27 Gene therapy delivering an adeno-DYRK1A construct
in liver rescued a normal level of homocysteine and of APO-AI,28
which is a regulator of inﬂammation. Brain inﬂammation seems to
be present also at early stages of AD: microglia activation is
observed in the dentate gyrus as early as the MCI stage.29
Therefore, decreased levels of plasma DYRK1A in AD patients
might contribute to increased inﬂammation related to amyloid
accumulation, maybe at a preclinical stage of the disease when
cortical amyloid deposition progressed.
Lymphoblastoid cell lines are used often to investigate genetic
mechanisms. To begin to dissect a potential genetic contribution
of DYRK1A to AD pathology, we derived LCLs from individuals
with AD and control individuals. Relative DYRK1A expression was
lower in LCLs from AD patients than in those from controls, and
with the same order of magnitude as observed in plasma. These
immortalized cells, which are grown in cell culture medium, have
no direct relations with the tissues or cells producing DYRK1A in
plasma. Although it is too early to differentiate between a genetic
or epigenetic mechanism, these results together with the
observation that DYRK1A levels vary among the population,12
suggest that DYRK1A decrease might be a novel risk factor for AD.
Taken together, our results suggest that decreased expression
of DYRK1A in plasma may serve as a potential biomarker for AD
even at the MCI stage. Further studies on larger cohorts may help
establish the utility of DYRK1A plasma concentration as a new risk
factor, alone or in combination with other markers for the
diagnosis of AD. The predictive power of this factor will need
further experiments with larger cohorts to be established.
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